Antibodies

28 Apr 2019 Genexine and NeoImmuneTech Announce Dosing of First Patient in the Combination Trial of Hyleukin-7™ with Merck’s KEYTRUDA® in Triple-Negative Breast Cancer
28 Apr 2019 Alexion Receives Positive CHMP Opinion for ULTOMIRIS® (ravulizumab) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
26 Apr 2019 Merck Provides Update on Phase 3 KEYNOTE-062 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
24 Apr 2019 GT Biopharma (GTBP) Announces the Elimination of HIV Infected Cells Using its Tri-Specific Killer Engagers (TriKEs) in Preclinical Testing at the University of Minnesota
24 Apr 2019 Innovent Announces First Patient Dosed in Phase I Clinical Trial of IBI318 Bispecific Antibody in China
24 Apr 2019 Teva Announces Update on Fremanezumab Clinical Development for use in Episodic Cluster Headache
24 Apr 2019 AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of SKYRIZI™ (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis
24 Apr 2019 Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
23 Apr 2019 Molecular Templates Announces FDA Acceptance of IND Application for MT-5111, An Engineered Toxin Body Targeting HER2
23 Apr 2019 U.S. Food and Drug Administration Accepts Biologics License Application for Eptinezumab
23 Apr 2019 Lilly Announces Positive Top-Line Results for COAST-X, a 52-Week Placebo-Controlled Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
22 Apr 2019 FDA Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination With Inlyta® (axitinib) as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma (RCC)
19 Apr 2019 TAU BIO-LOGIC Announces Humanization of Picomolar Affinity Monoclonal Antibody Targeting TauC3 Protein for the Treatment of Alzheimer's Disease and Progressive Supranuclear Palsy
19 Apr 2019 Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis
19 Apr 2019 Nemolizumab Achieves Primary Endpoint in Phase 3 Clinical Study (Comparative Study) in Japan for the Treatment of Atopic Dermatitis
19 Apr 2019 Prothena Reports Results from the Phase 3 VITAL Amyloidosis Study of NEOD001 (birtamimab) in AL Amyloidosis
18 Apr 2019 Harpoon Therapeutics Doses First Patient with a Mesothelin-Targeting T cell Engager (HPN536) in Phase 1/2a Clinical Trial for Ovarian and Other Solid Tumor Cancers
18 Apr 2019 Innovent Announces First Patient Dosed in a Phase I Clinical Trial of IBI302 for the Treatment of Wet AMD
18 Apr 2019 Viela Bio Receives U.S. FDA Breakthrough Therapy Designation for Inebilizumab for Treatment of Neuromyelitis Optica Spectrum Disorder
16 Apr 2019 Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD
16 Apr 2019 Eureka Therapeutics Announces Publication of Preclinical Study Demonstrating Selective Depletion of Tregs Using Foxp3 Targeting TCR-mimic Antibody
15 Apr 2019 Zymeworks Opens Phase 2 Clinical Trial for ZW25 in First-Line HER2-Expressing Metastatic Gastroesophageal Cancers
13 Apr 2019 TRACON Pharmaceuticals Announces Termination of Phase 3 TAPPAS Trial Based on the Recommendation of the Independent Data Monitoring Committee
12 Apr 2019 Trogarzo® Receives Positive Recommendation from Scientific Advisory Group of CHMP in Europe
12 Apr 2019 FDA Approves Expanded Monotherapy Label for Merck’s KEYTRUDA® (pembrolizumab)

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top